Dickran Kazandjian, MD
Hematology & Oncology · Miami, FLNPI 1114096567
Payments from drug & device makers
Across 311 payments — averaging $26,921 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4.8M
- AbbVie$1.8M
- Regeneron$819K
- Sanofi US Services Inc.$403K
- Janssen Research & Development, LLC$219K
- Beigene, Ltd.$217K
- plus $96K from 17 others
Across 210 payments — averaging $1174.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$245K
- Pfizer$1K
- Amgen$679
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $4,845,503 |
| AbbVie | 47 | $1,772,457 |
| Regeneron | 19 | $819,206 |
| Sanofi US Services Inc. | 39 | $402,611 |
| Janssen Research & Development, LLC | 41 | $219,235 |
| Beigene, Ltd. | 32 | $217,325 |
| Beone Medicines Ltd. | 7 | $54,890 |
| Karyopharm Therapeutics Inc. | 22 | $13,591 |
| Gilead | 12 | $11,758 |
| Bristol Myers Squibb | 2 | $7,854 |
| Sanofi | 25 | $2,786 |
| Pfizer | 3 | $2,374 |
| Johnson & Johnson | 21 | $1,097 |
| Adaptive Biotechnologies Corporation | 11 | $1,028 |
| Janssen Scientific Affairs, LLC | 4 | $285 |
| GSK | 9 | $136 |
| E.r. Squibb & Sons, L.L.C. | 2 | $131 |
| Genentech USA, Inc. | 1 | $88 |
| Stemline Therapeutics Inc. | 1 | $69 |
| Beigene USA, Inc. | 1 | $66 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
How this compares
$8,372,568 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Miami
- Carl LandgrenMiami$47.8M
- Justin WattsMiami$7.9M
- Jaime MerchanMiami$7.9M
- Frances ValdesMiami$5.7M
- Manmeet AhluwaliaMiami$4.8M
- Izidore LossosMiami$4.4M
- Gerald SoffMiami$4.3M
- James HoffmanMiami$3.3M
- Ana Sandoval LeonMiami$3.2M
- Julio ChavezTampa$16.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.